Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Alexandra Perel-Winkler"'
Autor:
Alexandra Perel-Winkler, Regina Belokovskaya, Isabelle Amigues, Melissa Larusso, Nazia Hussain
Publikováno v:
Case Reports in Rheumatology, Vol 2015 (2015)
In phase I and II trials taxane chemotherapeutic agents reported side effects, including myelosuppression, peripheral edema, and fluid retention. With further use of these agents, studies in the late 1980s and early 1990s began to report peripheral n
Externí odkaz:
https://doaj.org/article/d821bc70825341748f640c6b6f90d001
Autor:
S Nguyen, Alexandra Perel-Winkler, Laura Geraldino-Pardilla, Anca Askanase, J Miceli, Kayla Neville, Jon T. Giles, George Danias, Thierry Dervieux, Teja Kapoor
Publikováno v:
Lupus. 28:862-867
Objectives Hydroxychloroquine (HCQ) is a key therapy in systemic lupus erythematosus (SLE). Medication non-adherence is reported in up to 80% of lupus patients and results in increased morbidity, mortality, and health care utilization. HCQ levels are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a68f43362b7ce8d224f87ef25254ae2c
https://doi.org/10.1177/0961203319851558
https://doi.org/10.1177/0961203319851558
Autor:
Laura Geraldino-Pardilla, Thania Perez-Recio, Alexandra Perel-Winkler, Afshin Zartoshti, Anca Askanase, Sabahat Bokhari
Publikováno v:
Lupus Science & Medicine
Objectives Cardiovascular diseaseand heart failure (CHF) are leading causes of death in systemic lupus erythematosus (SLE). The underlying mechanisms for increased CHF in SLE are unclear but myocardial inflammation and lupus myocarditis (LM) may play
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74aebbe87691b27dc93f62d50f957cb9
http://europepmc.org/articles/PMC6069920
http://europepmc.org/articles/PMC6069920
Autor:
Rachel Simon, Alexandra Perel-Winkler, Katherine G. Nickerson, Sabahat Bokhari, Ladan Fazlollahi
Publikováno v:
JCR: Journal of Clinical Rheumatology. :1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4eb314b668a52c52653f3b799ef810c
https://doi.org/10.1097/00124743-900000000-99220
https://doi.org/10.1097/00124743-900000000-99220
Autor:
Regina Belokovskaya, Alexandra Perel-Winkler, Nazia Hussain, Isabelle Amigues, Melissa Larusso
Publikováno v:
Case Reports in Rheumatology, Vol 2015 (2015)
Case Reports in Rheumatology
Case Reports in Rheumatology
In phase I and II trials taxane chemotherapeutic agents reported side effects, including myelosuppression, peripheral edema, and fluid retention. With further use of these agents, studies in the late 1980s and early 1990s began to report peripheral n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::653567d0480075356183991eed889598
https://doaj.org/article/d821bc70825341748f640c6b6f90d001
https://doaj.org/article/d821bc70825341748f640c6b6f90d001